Search for: [Abstract = "d 28,09 months, respectively. In the SCLC the average patient survived 16,17 and 17,18 months from diagnosis, in CAV and TOPO, respectively. Second\-line treatment for NSCLC is more cost\-effective with docetaxel than with other treatment regimen. High prices of erlotinib, pemetrexed and topotecan and small differences in life expectancy increased the cost effectiveness ratio and made new type of treatment less cost\-effective than standard therapy. Considering the differences in the prices of medicines and different finance systems of the health care in Poland and other countries in the world it is useful to carry out the pharmacoeconomic analyses."]

Number of results: 1